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Alkylating agents are generally highly reactive with
DNA but demonstrate limited DNA sequence selectivity.
In contrast, synthetic pyrrole-imidazole polyamides rec-
ognize specific DNA sequences with high affinity but are
unable to permanently damage DNA. An eight-ring hair-
pin polyamide conjugated to the alkylating moiety cy-
clopropylpyrroloindole, related to the natural product
CC-1065, affords a conjugate 1-CBI (polyamide 1-CBI
(1-(chloromethyl)-5-hydroxyl-1,2-dihydro-3H-benz[e]in-
dole) conjugate), which binds to specific sequences in
the minor groove of DNA and alkylates a single adenine
flanking the polyamide binding site. In this study, we
show that 1-CBI alkylates DNA in both plasmid and in-
tracellular minichromosomal form and inhibits DNA
replication under both cell-free and cellular conditions.
In addition, it inhibits cell growth and arrests cells in
the G2/M phase of the cell cycle.
Polyamides are synthetic DNA binding molecules designed
to recognize and bind to specific sequences in the minor groove
of the double helix with affinities comparable with those of
DNA-binding proteins (1, 2). Polyamides comprised of pyrrole
(Py)1 and imidazole (Im) amino acids are connected through a
-aminobutyric acid () linker to create a hairpin structure. An
Im/Py pair recognizes a GC base pair, and Py/Im recognizes a
CG base pair (3), whereas Py/Py is partially degenerate and
recognizes both AT and TA base pairs (4). Hairpin polyamides
have the potential to affect gene transcription by specifically
targeting promoters or other regulatory sequences. It has been
demonstrated that polyamides can bind TFIIIA binding sites
and interfere with 5 S RNA expression (5), inhibit replication of
human immunodeficiency type I virus (6), or block the Ets
binding site of the HER2/neu promoter (7). To date, there have
been few reports describing polyamide-induced down-regula-
tion of endogenous gene expression in intact cells, which may
be related to the observation that nuclear localization is cell
type-dependent (8). Likewise, inhibition of cell growth or anti-
tumor activity has not been reported. The fact that binding of
polyamides to DNA is reversible, and their inability to perma-
nently damage DNA may account for the absence of cellular
activities.
In contrast to polyamides, the cyclopropylpyrroloindole (CPI)
DNA alkylating agents represent a class of antitumor drugs
whose members include some of the most biologically active
agents (9). CPI drugs interact with the DNA minor groove in
A/T-rich sequences and alkylate the N3 position in adenine at
the 3 end of the binding site. They inhibit DNA replication
through cis- or trans-acting mechanisms, mainly at the stage of
initiation (10–16).
In an effort to design hybrid DNA-binding compounds that
covalently interact with DNA in a sequence-specific fashion,
polyamide 1 was conjugated with a DNA alkylating group
seco-CBI, an analog to the reactive moiety of CPI drugs (17).
The conjugate 1-CBI (ImImPyPy-(R)(S)-CBI-ImPyPyPy--Dp)
(see Fig. 1) binds a 6-bp site, 5-(A/T)GG(A/T)C(A/T)-3, and
alkylates a single adenine flanking the polyamide binding site
in a strand-selective manner (17). The sequence-specific DNA
alkylating agent that integrates two separate moieties, one for
DNA recognition and the other for alkylation, led us to further
investigate its biological activities. In this study, SV40 DNA
was utilized to assess the ability of 1-CBI to damage target
DNA and affect DNA function. Using SV40 virus, one can study
drug-induced DNA lesions and their effects on DNA replication
in the same well defined genome (5243 bp) under both cell-free
and cellular conditions (12–14, 18). Since SV40 DNA replicates
in cells using the cellular machinery, it provides a good model
for mammalian DNA replication. In addition, cell growth inhi-
bition and cell cycle progression arrest were observed after
1-CBI treatment of BSC-1 cells.
EXPERIMENTAL PROCEDURES
Reagents and Cell Cultures—1-CBI, a hairpin polyamide-seco-CBI
conjugate (see Fig. 1), was synthesized as described previously (17).
[-32P]ATP and [-32P]dATP were obtained from Amersham Bio-
sciences. Form I SV40 DNA was purchased from Invitrogen. BamHI
and proteinase K were from Roche Molecular Biochemicals. GeneScreen
membranes were obtained from PerkinElmer Life Sciences. SV40 large
T-antigen was purified from baculovirus-infected High-Five insect cells
(Invitrogen) according to a published procedure (19). BSC-1 cells (Afri-
can green monkey kidney cells) were grown in minimal essential me-
dium (MEM) with 8% fetal calf serum and 2% fetal bovine serum
(MEM-10). Human 293 cells (transformed embryonic kidney cells) were
grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal bovine serum (DMEM-10). All cell lines were maintained at 37 °C
in a 5–95% CO2-air incubator.
SV40 DNA Forms Conversion Assay—Naked SV40 DNA or SV40
minichromosomes (150 ng, isolated as described elsewhere (20, 21)) was
incubated at 37 °C with 1-CBI in 20 l of TE buffer for up to 16 h (naked
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DNA) or for 4 h (minichromosomes). No DNA strand breakage was
observed in controls for up to 16 h incubation at 37 °C. Following
treatment, minichromosomes were incubated with 1% SDS for 30 min
at 37 °C to dissociate nucleosomal-like structures. All samples were
extracted with phenol/chloroform/isoamyl alcohol (PCI, 25:24:1), precip-
itated with ethanol, and resuspended in TE buffer containing 150 mM
NaCl. Samples were then incubated at 70 °C for 2 h to convert alkylated
bases to DNA strand breaks. DNA was electrophoresed on 0.8% agarose
gels in 1 Tris-acetate electrophoresis (TAE) buffer for 16 h at 1 V/cm,
stained with 1 g/ml ethidium bromide, and quantitated using densi-
tometry and ImageQuaNT program (Amersham Biosciences).
Repetitive Primer Extension (RPE) Assay—The reaction was carried
out according to the published procedure (22, 23). The oligonucleotide
primer (5-GCAGCTCCAAAGGTTCCC-3) starting from position 1991
(reverse) on the SV40 genome was synthesized by the Biopolymer
Facility at Roswell Park Cancer Institute. The primer was end-labeled
with [-32P]ATP using T4 polynucleotide kinase, and excess radioactive
label was removed using a G25 MicroSpin column (Roche Molecular
Biochemicals). The amplification mixture consisted of 50 ng of treated
SV40 DNA, 0.5 M labeled primer, 1.5 mM MgCl2, 0.2 mM of each dNTP,
and 1 unit of TaqDNA polymerase in 1 polymerase buffer (Invitro-
gen). Reaction was carried out using 35 cycles of 30 s at 95 °C, 30 s at
55 °C, and 55 s at 72 °C. The dideoxy cycle sequencing reaction was
performed according to manufacturer’s instructions (SequiTherm Excel
II sequencing kit, Epicentre Technologies, Madison, WI) using the same
primer and non-treated SV40 DNA template. DNA fragments were
separated on an 8% polyacrylamide/8.3 M urea sequencing gel and then
visualized and quantitated using phosphorimaging techniques.
Cell-free SV40 DNA Replication Assay—Cell extracts were prepared
from exponentially growing 293 cells as described earlier (18). Briefly,
cells were harvested, washed twice with phosphate-buffered saline,
resuspended in hypotonic buffer (20 mM Hepes, pH 7.5, 1.5 mM MgCl2,
5 mM KCl, 1 mM dithiothreitol, and 0.2 mM phenylmethylsulfonyl fluo-
ride), disrupted by three rapid freeze/thaw cycles, and incubated on ice
for an additional 30 min. After removing the cell debris by centrifuga-
tion at 12,000  g for 15 min, protein concentration of the resulting
extract was determined using the Bradford method (Bio-Rad). Agent-
modified template DNA was prepared by incubating SV40 DNA (0.3 g,
form I) with 1-CBI at 37 °C for 16 h followed by PCI extraction and
ethanol precipitation as described. The replication reaction mixture
contained 50 g of 293 cell extracts, 30 ng of drug-treated SV40 DNA,
0.6 g of SV40 T-antigen, and 2 Ci of [-32P]dATP in replication buffer
(4 mM ATP, 0.2 mM CTP, 0.2 mM GTP, 0.2 mM UTP, 0.1 mM dCTP, 0.1
mM dGTP, 0.1 mM dTTP, 0.025 mM dATP, 7 mM MgCl2, 0.024 units of
creatine phosphokinase, and 40 mM phosphocreatine). After incubation
for 1 h at 37 °C, the replication products were isolated on a G50
MicroSpin column (Roche Molecular Biochemicals) and separated by
electrophoresis on a 0.8% agarose gel at 1 V/cm for 18 h in 1 TAE. Gels
were dried, and DNA replication products were quantitated following
exposure to a phosphorimaging screen.
Intracellular SV40 DNA Replication Assay—BSC-1 cells were seeded
at 3  105 cells per 60-mm dish and grown for 24 h until 70–80%
confluent. Cells were infected with SV40 virus (multiplicity of infec-
tion  1) in MEM containing 2% calf serum (MEM-2) for 2 h at 37 °C.
After virus-containing medium was removed, cells were incubated an
additional 22 h in fresh MEM-2. At 24 h after infection, 1-CBI was
added to the medium for 16 h treatment, and the SV40 DNA was
extracted from cells according to the modified Hirt extraction procedure
(24). In short, phosphate-buffered saline-washed cells were incubated
for 10 min at 37 °C in 0.5 ml of 25 mM Tris-HCl, 5 mM EDTA, and 1%
SDS containing 0.1 mg/ml RNase followed by an additional 30-min
treatment with proteinase K (final concentration, 1 mg/ml). Cellular
proteins were precipitated by the addition of 0.35 ml of 3 M CsCl, 1 M
potassium acetate, and 0.67 M acetic acid and incubation for 15 min on ice.
Supernatants recovered by centrifugation for 15 min at 13,000  g were
loaded onto Qiagen spin columns (Valencia, CA). Columns were washed
with 0.75 ml of 80 M potassium acetate, 10 mM Tris-HCl, 40 M EDTA,
and 60% ethanol, and SV40 DNA was recovered with 50 l of TE.
The effects of 1-CBI on SV40 DNA intracellular replication were
analyzed by neutral/neutral two-dimensional gel electrophoresis using
a previously described method (12). Briefly, SV40 DNA isolated from
virus-infected and 1-CBI-treated BSC-1 cells was digested with the
restriction enzyme BamHI that cuts the SV40 molecule only once.
Samples were electrophoresed on 0.6% agarose gels in 1 TAE and 0.1
g/ml ethidium bromide for 24 h at 0.7 V/cm. DNA was excised and
placed in a slot cut into the top of the second-dimension gel (1% agarose,
0.5 g/ml ethidium bromide in Tris-borate electrophoresis buffer (TBE))
perpendicular to the direction of the first-dimension gel. The second-
dimension gel was electrophoresed at 4 °C in 1 TBE and 0.5 g/ml
ethidium bromide for 19 h at 4 V/cm. The second-dimension gels were
subjected to Southern blotting, and blots were hybridized to an -32P-
labeled full-length linear SV40 DNA probe (1  106 cpm/ml) prepared
by the random priming of BamHI-linearized SV40 DNA using random
primed DNA labeling kit (Ambion, Austin, TX).
Cell Cycle Progression Assay—BSC-1 cells were treated with 1-CBI
for 16 h followed by an additional 24-h incubation in drug-free medium.
Cells fixed in 5 ml of ice-cold 75% ethanol at 20 °C overnight were
stained in sodium citrate buffer containing propidium iodide (50 g/ml,
Sigma) and RNaseA (100 g/ml, Roche Molecular Biochemicals) for 30
min at room temperature. The DNA content of the stained cells (104
cells/sample) was analyzed by flow cytometry using a FACScan (BD
Biosciences) with an excitation wavelength of 488 nm and a long pass
( 600 nm) emission filter and WinList 5.0 program (Verity Software
House, Topsham, ME).
Cell Growth Inhibition Assay—Conjugate-induced cell growth inhi-
bition was determined by assaying the cell number after 4 days of
continuous exposure. BSC-1 cells were plated on a 96-well plate at 103
cells/well and incubated for 24 h. Exponentially growing cells were
treated with the tested agents for 4 days. Cells were then fixed in 1:6
trichloroacetic acid at 4 °C for 1 h, stained with 0.4% sulforhodamine-B,
rinsed with 1% acetic acid, and suspended in 10 mM Tris. Cell growth
was quantitated based on the amount of cellular proteins measured as
an absorbance at 570 nm.
RESULTS
1-CBI Induces Thermolabile Lesions in SV40 DNA—1-CBI
is a polyamide-based ligand (Fig. 1) that contains a CBI moiety
related to the natural alkylating agent CC-1065 that binds and
alkylates DNA. Heating of alkylated DNA at 70 °C resulted in
strand breaks at the drug binding site (25–27). Whether simi-
lar heat-labile DNA lesions resulted from 1-CBI treatment was
determined using an SV40 forms conversion assay. In this
assay, induction of DNA strand breaks can be detected by
changes in DNA forms distribution using agarose gel electro-
phoresis. Conversion of fast migrating SV40 DNA form I (su-
percoiled circular) to slow migrating form II (nicked circular)
requires one strand break per DNA molecule, whereas the
FIG. 1. Structure of 1-CBI and model of its binding site. A,
chemical structure of polyamide-CBI conjugate 1-CBI. B, model of
polyamide conjugate bound to the match site 5-TGGTCA-3. Shaded
and non-shaded circles represent imidazole and pyrrole rings, respec-
tively, the diamond represents -alanine, and the hatched triangle
represents (S)-CBI.
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formation of form III (linear) requires a frank double-strand
break or at least two single-strand breaks, closely spaced on
opposite strands.
The ability of 1-CBI to damage SV40 DNA is shown in Fig.
2. After incubating DNA for 16 h with 1 M 1-CBI at 37 °C,
DNA lesions can be converted to strand breaks by heating at
70 °C. The 2 h of heating resulted in the quantitative conver-
sion of the alkylated form I SV40 DNA to form II and form III,
while leaving non-treated control DNA undamaged (Fig. 2A,
lane 2). First, the time dependence of DNA alkylation by 1-CBI
was determined at 37 °C. As shown in Fig. 2A, DNA damage
can be detected after a 1–2-h incubation at 37 °C, as indicated
by a loss of form I molecules and increases in form II and form
III (lanes 5 and 6). A complete loss of form I and significant
increase in form III were observed only after a 16-h incubation.
The results demonstrate that DNA alkylation is time-depend-
ent and that a 16-h 1-CBI incubation produces maximum DNA
lesions. Therefore, unless otherwise indicated, a 16-h treat-
ment with 1-CBI was used in the subsequent studies.
Next, the dose dependence of 1-CBI-induced DNA damage
was evaluated (Fig. 2B). SV40 DNA was treated for 16 h at
37 °C with increasing concentrations of 1-CBI. The quantita-
tion of the gels showed that at 0.1 M, the amount of super-
coiled DNA (form I) was reduced by 50%, whereas 0.2 M
1-CBI converted more than 90% of the supercoiled DNA to
forms II and III. Treatment with higher concentrations of the
agent resulted in a significant increase in the form III band (2
M, lane 7), suggesting alkylation of the closely spaced sites,
which can be converted to double-strand break. Under the
same experimental conditions, no DNA strand damage was
observed with parent polyamide 1, which binds reversibly to
DNA but cannot alkylate it (data not shown).
1-CBI Alkylates SV40 Minichromosomal DNA—1-CBI alky-
lation of naked SV40 DNA and SV40 minichromosomes was
compared to determine whether DNA association with nucleo-
proteins affected alkylation. SV40 minichromosomes are
formed in cells during lytic infection, when the viral genome
associates with histones and other nuclear proteins to form
circular molecules of nucleosomal chromatin. Minichromo-
somes provide a good model of mammalian chromatin in vitro
because the virus uses the chromatin components of the host,
and the minichromosomes with their full complement of DNA-
associated proteins can be separated from the cellular genome.
However, to examine DNA alkylating activity on chromatin
structure, it is necessary to define a condition that can prevent
1-CBI from binding to DNA during the post-lysis period. Since
it is experimentally difficult to remove free agent from
minichromosomes after the reaction, there is a possibility that
1-CBI could bind naked DNA after dissociating nucleoprotein
from the minichromosomal DNA. A previous study showed that
some detergents, including SDS, are able to prevent CPI drugs
from binding to DNA (27). Likewise, 1% SDS effectively pre-
vented 1-CBI from binding to SV40 DNA without causing
removal of 1-CBI already covalently bind to DNA (data not
shown).
1-CBI alkylating activity on minichromosomal SV40 DNA
was determined by the forms conversion assay (Fig. 2C), using
SDS to prevent free agent from binding to DNA once nucleo-
proteins had been dissociated from minichromosomes. SV40
minichromosomes were treated with increasing concentrations
of 1-CBI at 37 °C for 4 h (longer incubation at 37 °C resulted in
disruption of minichromosomal structure) followed by the ad-
dition of 1% SDS for an additional 30 min. After free agent and
proteins were removed by PCI extraction and ethanol precipi-
FIG. 2. 1-CBI-induced damage in na-
ked and minichromosomal SV40
DNA. Minichromosomal or naked SV40
DNA was treated with 1-CBI at 37 °C,
purified, and then redissolved in TE
buffer containing 150 mM NaCl. DNA le-
sions were converted to strand breaks by
heating at 70 °C for 2 h. All samples were
subjected to agarose gel electrophoresis
followed by ethidium bromide staining
and forms quantitation. The positions of
DNA forms I, II, and III are indicated. A,
time dependence. Lanes 1 and 2, non-
treated control DNA. Lanes 3–7, DNA
treated with 1 M 1-CBI at 37 °C for 0–16
h. B, dose dependence. DNA was treated
at 37 °C for 16 h with 0–2 M 1-CBI as
indicated and then subjected to 70 °C
for 2 h. C, 1-CBI-induced damage in
minichromosomal SV40 DNA. SV40
minichromosomes were treated with
1-CBI (0–2 M) at 37 °C for 4 h. 1% SDS
was then added to all samples for an
additional 30 min except that in lane 8,
1% SDS was present in the solution be-
fore the addition of 1-CBI.
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tation, strand breaks were induced by heating the alkylated
DNA at 70 °C for 2 h. 1-CBI damages minichromosomal DNA
in a dose-dependent manner, as demonstrated in Fig. 2C. Fifty
percent conversion of DNA form I to II and III was calculated
from quantitated gels at 0.18 M 1-CBI, the range similar to
that observed for naked SV40 DNA. Thus, 1-CBI appears to be
equally effective at alkylating both naked and minichromo-
somal DNA. Confirmation that 1-CBI could be prevented from
binding DNA by 1% SDS was obtained when the detergent was
added to the minichromosomes prior to the agent, resulting in
no detectable increase in DNA damage (Fig. 2C, lane 8).
Sequence Specificity of 1-CBI-induced DNA Damage—Natu-
rally occurring CPI compounds alkylate N-3 of adenine within
AT-rich regions, thereby exhibiting sequence preference but
not sequence specificity (28). The polyamide portion of 1-CBI is
designed to bind a specific DNA sequence, 5-(A/T)GG(A/T)C(A/
T)-3. This binding positions the agent to alkylate a single
adenine located 2 bp away from the polyamide-targeting site.
The sequence-specific alkylation by 1-CBI has been confirmed
previously on a 277-bp DNA fragment (17). To further test this
characteristic on a more complex DNA molecule (5243 bp), the
RPE assay was performed using agent-treated SV40 DNA as a
template. In this assay, DNA nascent chain elongation driven
by polymerase stops at sites of the damage on template DNA,
and the partial DNA synthesis products indicate the positions
of DNA damage (22).
Initially, naked SV40 DNA was treated with 1-CBI for 16 h
at 37 °C and then extracted and precipitated to remove free
1-CBI. Agent-modified and control non-treated DNA was used
as template in linear amplification reactions. The experiments
demonstrated that 1-CBI induced DNA damage in vitro at the
specific site, the polyamide-targeted site (Fig. 3). One M 1-CBI
effectively damaged DNA at an adenine site 2 bp adjacent to
the polyamide binding site, 5-AGGACTTA-3 (Fig. 3, lane 7,
the arrow indicates presumed alkylated adenine). The parent
polyamide 1 (at 3 M) did not induce DNA damage under the
same experimental conditions (data not shown). It was also
noted that 1-CBI introduced DNA damage at a site composed
of six contiguous adenines but not at other AT-rich regions in
the analyzed DNA fragment.
To compare 1-CBI sequence specificity in cellular and cell-
free environments, the RPE assays were performed using SV40
DNA isolated from virus-infected and then agent-treated
BSC-1 cells (Fig. 3, lane 6). At 24 h after infection with SV40,
BSC-1 cells were treated with 1-CBI for 16 h, and SV40 DNA
was isolated as described under “Experimental Procedures.”
FIG. 3. Sequence specificity of 1-CBI-indced DNA damage. Na-
ked SV40 DNA or SV40-infected BSC-1 cells were treated with 1-CBI
for 16 h, and then DNA was isolated, purified, and subjected to RPE
reaction as described under “Experimental Procedures.” The CTAG
lanes (lanes 1–4) represent the results of sequencing reactions using the
same DNA primers. Lane 5, control, DNA from SV40-infected and
mock-treated cells; lane 6, DNA from SV40-infected cells treated with 1
M 1-CBI; lane 7, naked SV40 DNA treated with 1 M 1-CBI. The
positions of the alkylated adenines flanking polyamide-targeted sites
(bold) are indicated by arrows.
FIG. 4. 1-CBI-induced inhibition of SV40 DNA replication in
cell-free system. Replication reactions were assembled using 50 ng of
SV40 DNA treated for 16 h with 1-CBI, 30 g of extract of 293 cells, and
0.6 g of SV40 T-antigen and incubated at 37 °C for 1 h. Replication
products were purified, resolved on 0.8% neutral agarose gels (A), and
quantitated (B) as described under “Experimental Procedures.” Posi-
tions of plasmid topoisomers (TI) and replication intermediates (RI) are
indicated. The data points in the chart represent the average of three
independent experiments.
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The experiments showed that 1-CBI alkylates the same DNA
sequence on intracellular SV40 as on naked DNA (lanes 6 and
7). Since cell lysis was performed in the presence of 1% SDS,
which prevents rebinding to DNA as described earlier in the
cell-free study, we conclude that post-lysis 1-CBI-DNA inter-
actions did not contribute to the SV40 DNA damage observed.
Inhibition of Cell-free SV40 DNA Replication—1-CBI in-
duces DNA lesions that could stop DNA polymerase, as shown
in RPE experiments. Therefore, whether 1-CBI-alkylated
SV40 DNA could serve as a template in the more complex DNA
synthesis system (such as cell-free SV40 DNA replication) was
examined (Fig. 4A). Naked SV40 DNA was treated with 1-CBI
for 16 h at 37 °C followed by removal of free 1-CBI. The repli-
cation reaction containing extracts of 293 cells, control, or
agent-treated SV40 DNA template and SV40 T-antigen was
carried out as described under “Experimental Procedures.” Re-
duced DNA replication competence was noted when the SV40
DNA template was treated with 0.1 M 1-CBI (lane 2), and the
reduction was maximal with 0.5–1 M 1-CBI (lanes 4 and 5).
The inhibition curve (Fig. 4B) shows that 0.25 M 1-CBI de-
creased SV40 DNA replication by 50%. Since the cell extract
was not agent-treated and free agent was removed after tem-
plate treatment, the inhibition of replication activity is likely
due to 1-CBI-induced covalent damage to the DNA template.
No inhibition of SV40 DNA replication was detected when the
SV40 DNA template was pretreated with up to 10 M polyam-
ide 1 (data not shown).
Inhibition of SV40 DNA Replication in BSC-1 Cells—Since it
was found that 1-CBI inhibited cell-free SV40 replication, we
examined whether similar activity can be observed in the intact
cells. It has been shown by two-dimensional gel electrophoresis
that CPI drugs can block intracellular SV40 replication at the
level of initiation (12, 14). At 24 h after infection with SV40,
BSC-1 cells were treated with 1-CBI for 16 h, and the isolation
of SV40 DNA was carried out as described. Naked DNA was
separated on two-dimensional gel electrophoresis and analyzed
as described under “Experimental Procedures.” 1-CBI treat-
ment caused a concentration-dependent decrease in intracellu-
lar SV40 replication intermediates detected in the form of
bubble arc, as indicated by the arrows in Fig. 5; the bubble arc
intensity was reduced at 0.1 M and diminished completely at
3–10 M agent concentration.
Cell Cycle Arrest Induced by 1-CBI—One of the cellular
responses following DNA damage induced by CPI agents is a
delay in S phase and block at the G2/M transition in the cell
cycle (29). Flow cytometry was used to evaluate the cell cycle
progression of BSC-1 cells treated with 1-CBI. Asynchronously
growing cells were treated with 1-CBI for 16 h and postincu-
bated in agent-free medium for 24 h, and then cellular DNA
was stained with propidium iodide, and DNA content was
analyzed by flow cytometry (Fig. 6). In control non-treated
samples, the majority of cells were in G1 (62%) with the
remaining distributed through S and G2/M. With the increase
of 1-CBI concentration, the delayed progression through S and
the G2/M arrest were observed. Twenty-four h after treatment
with 1 M 1-CBI, the majority of cells were in late S (55%)
and G2/M (30%). Under similar conditions, no effects on cell
cycle were observed in BSC-1 cells treated with polyamide 1
(data not shown).
Cell Growth Inhibition by 1-CBI—Since 1-CBI exhibited the
ability to damage and interfere with DNA functions in whole
cells, one can expect that it is capable of inhibiting cell growth.
Growth of BSC-1 cells following 1-CBI treatment was meas-
ured using standard sulforhodamine-B staining of cellular pro-
teins. The cell growth curve (Fig. 7) shows that 0.3 M 1-CBI
inhibits cell growth by 50%, whereas polyamide 1 has no effect
up to 10 M. To address the possible cell line specificity of this
activity, the cell growth inhibition induced by 1-CBI was also
analyzed using human 293 and NIH3T3 (mouse embryonic
fibroblasts) cells. Similar levels of growth inhibition were ob-
served in all tested cell lines at 0.1–10 M 1-CBI concentrations
(data not shown).
In addition, the ability of 1-CBI to inhibit cell growth was
evaluated using a pair of human breast cancer cell lines,
MDA435/LCC6 wild type and MDA435/LCC6 multidrug-resist-
ant (MDR) (30). As compared with the wild type (sensitive) cell
line, 3.5-fold higher concentration of 1-CBI is required to
inhibit the growth of MDR cells by 50% (IC50) (Table I). By
comparison, a 12-fold higher concentration of the DNA cross-
linking CPI agent bizelesin was required to inhibit growth of
the MDR cell line as compared with the wild type cell line,
whereas both cell lines were equally sensitive to CC-1065 and
adozelesin (monoalkylating CPI agents).
DISCUSSION
In the current study, we evaluated the DNA binding agent
1-CBI, which combines the sequence specificity of a polyamide
FIG. 5. Effects of 1-CBI on intracel-
lular SV40 DNA replication. SV40-in-
fected BSC-1 cells were treated for 16 h
with the indicated concentrations of
1-CBI (0–10 M). Purified SV40 replica-
tion intermediates were separated by
two-dimensional agarose gel electro-
phoresis, detected by Southern blotting
and hybridization to [32P]-SV40 probe,
and analyzed as described under “Exper-
imental Procedures.” The positions of rep-
lication intermediates (bubble arcs) are
indicated by arrows.
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and the alkylating function of a CPI agent. A prior study
provided information on the ability of 1-CBI to alkylate a
target sequence contained within a short linear DNA molecule
(17). The degree to which this agent can interact and alkylate
more complex DNA structures and how the ability to damage
DNA translates into its biological activity are described in this
study.
Analysis of DNA damage using an SV40 forms conversion
assay showed that 1-CBI alkylates DNA after incubation at
37 °C and that lesions can be converted to strand breaks by
heating alkylated DNA at 70 °C for 2 h. The DNA damaging
activity of 1-CBI is only 2–3-fold less than that of its parent
alkylating agent CC-1065 based on the conversion of 50% of
form I SV40 (0.1 versus 0.05 M) (Fig. 2, A and B, and Ref.
27). However, a 16-h incubation is required to produce the
maximum amount of DNA damage, whereas only 15 min is
needed for maximal CC-1065-induced damage (27). Examina-
tion of the form conversion data obtained using naked (Fig. 2,
A and B) and minichromosomal (Fig. 2C) DNA indicated that
the presence of chromatin structure components had little ef-
fect on the level of damage introduced by 1-CBI. In addition,
supercoiled DNA (form I) was converted predominantly to
nicked circular DNA (form II), and a significant increase in
linear form III was observed only at higher 1-CBI concentra-
tions (1 M). Since conversion from form I to II requires one
single-strand break, these results indirectly confirm the mono-
alkylating activity of 1-CBI.
Classical CPI agents target the N-3 of adenine on DNA (28),
and their DNA sequence selectivity is limited to the AT-rich
region (27). The polyamide moiety of 1-CBI, however, is de-
signed to target the agent to specifically alkylate a single
adenine flanking the polyamide binding site 5-(A/T)GG(A/
T)C(A/T)-3. Our cell-free RPE experiments using 1-CBI-
treated DNA showed that a single adenine was alkylated in a
dose-dependent fashion in the analyzed SV40 DNA region. The
alkylated adenine is 2 bp away from the 3-terminal of the
polyamide-binding sequence 5-AGGACT-3 (Fig. 3, lane 7).
Furthermore, similar sequence specificity was observed on an
intracellular SV40 DNA target that was isolated from 1-CBI-
treated, SV40 virus-infected cells (Fig. 3, lane 6). Therefore, the
ability of 1-CBI to alkylate a polyamide-specific DNA sequence
in both cell-free and intracellular environments has been dem-
onstrated. These results are consistent with earlier findings
which showed that CPI agents produce similar DNA damage
profiles regardless of whether the target is naked or nucleoso-
mal DNA (11, 27). We note in the RPE analysis (Fig. 3, lower
part of the gel) that 1-CBI introduces lesions at two adenines in
the 5-AAAAAA-3 tract proximal to a polyamide match se-
quence 5-GGACA-3.
One biological activity often associated with DNA damaging
agents is their ability to inhibit DNA replication via a cis-acting
mechanism due to the presence of lesions on the replicating
template. We studied drug-induced inhibition of DNA replica-
tion under cell-free conditions using SV40 templates treated
with 1-CBI. Replication inhibition was observed at concentra-
tions as low as 0.1 M (Fig. 4). At the same concentration range,
50% of SV40 DNA form I was converted to form II and form
III in the forms conversion assay (Fig. 2), indicating that 50%
FIG. 6. Effects of 1-CBI on BSC-1 cell cycle progression. BSC-1
cells were treated with 1-CBI (0.01–1 M) for 16 h followed by an
additional 24-h incubation after removal of free 1-CBI. Cellular DNA
content was evaluated by flow cytometry as described under “Experi-
mental Procedures.”
FIG. 7. Cell growth inhibition induced by 1-CBI and polyamide
1. BSC-1 cells were treated with 1-CBI (shaded circles) or polyamide 1
(open circles) continuously for 4 days. The percentage of inhibition of
cell growth was determined using standard sulforhodamine methodol-
ogy as described under “Experimental Procedures.” The data points
represent the average of at least three independent experiments done in
triplicate.
TABLE I
Growth inhibition induced by 1-CBI and related CPI agents
in sensitive (MDA435/LCC6) and multidrug-resistant
(MDA435/LCC6 MDR) human breast cancer cell lines
Agent
MDA435/LCC6 MDA435/LCC6 Ratio
IC50
a IC50 (MDR/sensitive)
1-CBI 0.36 M 1.23 M 3.5
CC-1065 6.3 nM 6.1 nM 0.9
Adozelesin 6.1 nM 6.9 nM 1.1
Bizelesin 11 pM 132 pM 12
a Cells were agent-treated for 4 days, and then the growth was
quantitated based upon sulforhodamine-B staining of cellular proteins
and absorbance measurements at 570 nm as described under “Experi-
mental Procedures.”
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of SV40 DNA molecules acquired at least one DNA lesion,
rendering them inactive in the replication assay. Our results
showed that the 1-CBI concentrations required for DNA repli-
cation inhibition and DNA damage in cell-free system are sim-
ilar, suggesting direct relationships between both events.
However, the accessibility of cellular DNA to the alkylation
by 1-CBI might be limited by factors such as cell membrane
permeability or protein interference. To explore 1-CBI-induced
inhibition of DNA replication under cellular conditions, two-
dimensional electrophoresis gel analysis was performed using
the well defined SV40 DNA replication system in BSC-1 cells.
This technique had been used in previous studies to demon-
strate that CPI agents, adozelesin (12) and bizelesin (14), can
inhibit cellular DNA replication at the level of initiation. Like
these CPI agents, inhibition of intracellular SV40 DNA repli-
cation by 1-CBI was indicated by a loss of replication interme-
diates with increasing 1-CBI concentration (Fig. 5). Although
this profile is consistent with a blockage of the initiation of
DNA replication, further studies would be needed to verify the
effects on elongation.
Another consequence of exposing cells to 1-CBI is interfer-
ence with cell cycle progression. Previous studies showed that
cells treated with DNA-alkylating CPI agents slow their pro-
gression through S phase and arrest in the G2/M phase of cell
cycle (29). Our flow cytometry results clearly indicated that
1-CBI delayed S-phase progression and blocked cells in G2/M
phase (Fig. 6).
The potency of a DNA damaging agent is related to its
cytotoxic potential. Although 1-CBI shows the ability to inhibit
cell growth (Fig. 7), it requires a 50-fold higher concentration of
the hybrid compound to inhibit cell growth in comparison with
the classical CPI agents (31). This could be partially explained
by the relatively large molecular weight of 1-CBI, which may
hinder its cellular uptake. Nevertheless, since the parent pol-
yamide 1 was virtually inactive even at higher concentrations
(10 M), this finding demonstrates that addition of the alky-
lating activity to the polyamide confers an ability to inhibit cell
growth. The cell growth inhibition of 1-CBI was observed at
levels similar to those required for the detection of cellular
DNA damage, DNA replication inhibition, and cell cycle arrest
in BSC-1 cells. This is distinct from previous reports with some
CPI agents in which cell growth inhibition was observed at
much lower levels than those required for the detection of
either DNA damage or DNA synthesis inhibition (13, 32).
Previous studies showed that the MDR phenotype could af-
fect the activity of CPI drugs (31). As compared with the wild
type cell line, the 12-fold higher concentration of bizelesin was
required to inhibit the growth of MDR cells in 50%. On the
other hand, adozelesin or CC-1065 was equally active against
sensitive and MDR-resistant cells. Interestingly, 1-CBI evoked
intermediate differences between sensitive and resistant cells
(3.5-fold). We hypothesize that the deviation of 1-CBI from
patterns established for other mono-alkylating CPI drugs (ado-
zelesin and CC-1065) could be partial related to its higher
sequence selectivity.
The high binding affinity and sequence specificity of poly-
amides suggest that they may be useful in both basic research
and drug development. Although the displacement of transcrip-
tion factors by polyamides under cell-free conditions has been
observed, there are few reports of cellular responses that result
from the actions of polyamides in whole cells. Our study sug-
gests that 1-CBI can target cellular DNA in a sequence-specific
fashion and exert an effect on DNA replication, cell cycle, and
cell growth. The polyamide-CBI conjugate combines the char-
acteristics of both parent compounds and yet possesses novel
activity in intact cells. Whether conjugates of this type have the
potential to target specific genes in cell culture remains an
open question and will be reported in due course.
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